PURPOSE: This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic fever patients colonized with VRE and to determine patient characteristics associated with VRE infection. METHODS: We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy. RESULTS: Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks. CONCLUSION: For patients colonized with VRE, approximately 38% of high-risk neutropenic patients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenic patients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.
PURPOSE: This study seeks to determine the incidence of vancomycin-resistant enterococci (VRE) infection in high-risk neutropenic feverpatients colonized with VRE and to determine patient characteristics associated with VRE infection. METHODS: We conducted a retrospective, single-center, unmatched case-control study. Fifty-three VRE-colonized, high-risk patients with neutropenic fever were identified between January 2006 and February 2009. The two most common diagnoses/conditions included acute myeloid leukemia and hematopoietic stem cell transplantation. Data collected included days of neutropenia, days of fever, demographic data, culture results, and antimicrobial therapy. RESULTS: Twenty of the 53 patients (38%) with VRE colonization developed a VRE infection. The most common VRE infections were bacteremias (26%). The presence of neutropenia lasting longer than 7 days was associated with the development of VRE infection in this high-risk population colonized with VRE. The timeframe to develop VRE infection varied from 1 day to 2 weeks. CONCLUSION: For patients colonized with VRE, approximately 38% of high-risk neutropenicpatients developed a VRE infection. This is the first study to specifically evaluate the incidence of VRE infections in febrile neutropenicpatients colonized with VRE. Future research into the use and efficacy of empiric VRE coverage is needed.
Authors: Walter T Hughes; Donald Armstrong; Gerald P Bodey; Eric J Bow; Arthur E Brown; Thierry Calandra; Ronald Feld; Philip A Pizzo; Kenneth V I Rolston; Jerry L Shenep; Lowell S Young Journal: Clin Infect Dis Date: 2002-02-13 Impact factor: 9.079
Authors: P F Smith; M C Birmingham; G A Noskin; A K Meagher; A Forrest; C R Rayner; J J Schentag Journal: Ann Oncol Date: 2003-05 Impact factor: 32.976
Authors: S M Bhavnani; J A Drake; A Forrest; J A Deinhart; R N Jones; D J Biedenbach; C H Ballow Journal: Diagn Microbiol Infect Dis Date: 2000-03 Impact factor: 2.803
Authors: Branimir Jaksic; Giovanni Martinelli; Jaime Perez-Oteyza; Charlotte S Hartman; Linda B Leonard; Kenneth J Tack Journal: Clin Infect Dis Date: 2006-01-25 Impact factor: 9.079
Authors: Stanton L Gerson; Sheldon L Kaplan; Jon B Bruss; Vu Le; Felix M Arellano; Barry Hafkin; David J Kuter Journal: Antimicrob Agents Chemother Date: 2002-08 Impact factor: 5.191
Authors: B J Liss; J J Vehreschild; O A Cornely; M Hallek; G Fätkenheuer; H Wisplinghoff; H Seifert; M J G T Vehreschild Journal: Infection Date: 2012-06-05 Impact factor: 3.553
Authors: Truc T Tran; Hannah R Palmer; Marion R Weimar; Cesar A Arias; Gregory M Cook; Barbara E Murray Journal: Clin Infect Dis Date: 2015-02-19 Impact factor: 9.079
Authors: Jan Vydra; Ryan M Shanley; Ige George; Celalettin Ustun; Angela R Smith; Daniel J Weisdorf; Jo-Anne H Young Journal: Clin Infect Dis Date: 2012-06-12 Impact factor: 9.079
Authors: Diana Averbuch; Christina Orasch; Catherine Cordonnier; David M Livermore; Malgorzata Mikulska; Claudio Viscoli; Inge C Gyssens; Winfried V Kern; Galina Klyasova; Oscar Marchetti; Dan Engelhard; Murat Akova Journal: Haematologica Date: 2013-12 Impact factor: 9.941
Authors: E Montassier; E Batard; T Gastinne; G Potel; M F de La Cochetière Journal: Eur J Clin Microbiol Infect Dis Date: 2013-01-25 Impact factor: 3.267
Authors: Olaf Penack; Carolin Becker; Dieter Buchheidt; Maximilian Christopeit; Michael Kiehl; Marie von Lilienfeld-Toal; Marcus Hentrich; Marc Reinwald; Hans Salwender; Enrico Schalk; Martin Schmidt-Hieber; Thomas Weber; Helmut Ostermann Journal: Ann Hematol Date: 2014-04-29 Impact factor: 3.673